Amidst a share value slump and executive turmoil, Pfizer reported a robust quarter thanks in part to Covid-19 drug sales.
Pfizer reports Q3 EPS of $1.06, surpassing $0.62 consensus, with revenue up 31% to $17.7 billion. Growth driven by Paxlovid, ...
A boost from COVID-19 treatment sales helped bush Pfizer to a better-than-expected third quarter and higher forecast for the ...
Pfizer Inc (PFE) reports a 32% operational revenue growth and raises full-year guidance, despite challenges in COVID-19 ...
Pfizer (PFE) stock fell even as the company beat forecasts with its Q3 results and increased its full-year outlook.Find out ...
TipRanks on MSN12h
Pfizer Inc. Reports Strong Q3 2024 Results, Raises GuidancePfizer Inc ( ($PFE) ) has realeased its Q3 earnings. Here is a breakdown of the information Pfizer Inc presented to its ...
In Tuesday's pre-market trade, Pfizer's ( PEE, Financial) shares edged up following a strong third-quarter earnings report ...
The company’s updated guidance for revenue includes approximately $10.5B in anticipated revenues for Comirnaty and Paxlovid, ...
Pfizer PFE reported third-quarter 2024 adjusted earnings per share of $1.06, which crushed the Zacks Consensus Estimate of 64 ...
Pfizer (PFE) stock gained after the company beat estimates with its Q3 2024 financials and raised its full-year guidance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback